(Q50271158)

English

Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study

scientific article published in October 2017

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/28961832

Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/28961832

pancreatic cancer

1 reference

based on heuristic

inferred from title

author name string

B Schultheis

1

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/28961832

D Reuter

2

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/28961832

M P Ebert

3

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/28961832

J Siveke

4

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/28961832

A Kerkhoff

5

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/28961832

W E Berdel

6

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/28961832

R Hofheinz

7

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/28961832

D M Behringer

8

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/28961832

W E Schmidt

9

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/28961832

E Goker

10

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/28961832

S De Dosso

11

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/28961832

M Kneba

12

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/28961832

S Yalcin

13

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/28961832

F Overkamp

14

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/28961832

F Schlegel

15

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/28961832

M Dommach

16

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/28961832

R Rohrberg

17

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/28961832

T Steinmetz

18

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/28961832

Michael Bulitta

19

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/28961832

D Strumberg

20

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/28961832

publication date

1 October 2017

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/28961832

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/28961832

28

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/28961832

10

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/28961832

2429-2435

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/28961832

European cancer mortality predictions for the year 2013.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX343

21 January 2018

Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX343

21 January 2018

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX343

21 January 2018

Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX343

21 January 2018

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX343

21 January 2018

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX343

21 January 2018

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX343

21 January 2018

Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX343

21 January 2018

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX343

21 January 2018

Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX343

21 January 2018

Don't jump to rash conclusions.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX343

21 January 2018

Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX343

21 January 2018

Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX343

21 January 2018

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX343

21 January 2018

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX343

21 January 2018

Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX343

21 January 2018

Identifiers

10.1093/ANNONC/MDX343

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/28961832

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 February 2018

http://europepmc.org/abstract/MED/28961832

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50271158&oldid=2246888442"